ReviewIn vivo (Athens, Greece)
Textbook Outcome/Textbook Oncological Outcome for Pancreatic Cancer Treatment.
Review in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic surgery is an essential treatment for resectable pancreatic ductal adenocarcinoma (PDAC). However, perioperative morbidity and mortality are higher, and postoperative hospital stays are longer, than those for other gastrointestinal malignancies. Meanwhile, the quality of the perioperative surgical course affects both short- and long-term oncological outcomes in various malignancies.Recently, the concepts of textbook outcome (TO) and textbook oncological outcome (TOO) have been developed to evaluate the quality of perioperative surgical care. TO and TOO incorporate multiple perioperative elements and have been applied across various malignancies. In PDAC surgery, TO was defined in 2020 and consists of six short-term surgical outcomes: absence of postoperative pancreatic fistula, bile leak, post-pancreatectomy hemorrhage, severe complications (Clavien-Dindo grade ≥III), readmission, and in-hospital mortality.Previous studies have demonstrated that achieving TO or TOO is associated with improved survival after pancreatic surgery for PDAC. To optimize pancreatic surgery for resectable PDAC, it is essential to understand the characteristics and limitations of existing studies conducted prior to the widespread adoption of TO and TOO. This review summarizes the background, current status, and future perspectives of TO and TOO in pancreatic surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.